银花泌炎灵片用于泌尿系梗阻的精准人群及用药特征的真实世界研究  

Yinhua Miyanling Tablet Prescription Characteristics and its Targeted Population with Urinary System Obstruction Based on Real-world Study

作　　者：赵凤英 朱健 张利丹 谢雁鸣[1] 吕健 贾萍萍[3] ZHAO Fengying;ZHU Jian;ZHANG Lidan;XIE Yanming;LYU Jian;JIA Pingping(Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences,Beijing 100700,China;Guang′anmen Hospital,China Academy of Chinese Medical Sciences,Beijing 100053,China;School of Statistics,Renmin University of China,Beijing 100872,China)

机构地区：[1]中国中医科学院中医临床基础医学研究所,北京100700 [2]中国中医科学院广安门医院,北京100053 [3]中国人民大学统计学院,北京100872

出　　处：《世界中医药》2022年第4期531-536,共6页World Chinese Medicine

基　　金：国家重点研发计划项目(2018YFC1707400)——十种中成药大品种和经典名方上市后治疗重大疾病的循证评价及其效应机制的示范研究;中国中医科学院自主选题项目(Z0605)——清热解毒中药(上焦)及清热利湿中药(下焦)对细菌性疾病抗耐药疗效机制研究。

摘　　要：目的:分析银花泌炎灵片治疗泌尿系梗阻(UTO)患者的精准人群及用药特点。方法:基于中国部分各大医院HIS集成的数据仓库,提取2006年2月至2015年12月来自中国16家大型综合性三甲医院HIS所记录的利用银花泌炎灵片治疗UTO患者823例信息。对其临床用药信息采用基于Apriori算法的关联规则分析。结果:分析HIS数据库后得出,UTO患者中女性(61.10%)占比高于男性(38.90%),其中以45~65岁患者为主,常合并泌尿系结石等其他疾病,使用银花泌炎灵片单次剂量以2 g(4片)为主,每日剂量以2.5~4 g(5~8片)者占87.99%,疗程7 d以下者占74.50%,出院转归治愈好转者占97%。结论:炎症反应导致UTO是银花泌炎灵片的治疗精准人群,银花泌炎灵片治疗UTO91.7%需联合抗生素治疗,银花泌炎灵与抗生素联合用药方案可结合药敏检测结果选择联合青霉素和氨曲南,或联合青霉素和头孢地尼,或联合哌拉西林钠舒巴坦钠;将近1/2的UTO患者需联合中成药清热剂进行治疗,需联合补益剂的占20.90%,联合通淋排石剂占11.06%。Objective:To analyze the target population of Yinhua Miyanling tablet in the treatment of patients with urinary system obstruction and the characteristics of prescription.Methods:Based on HIS large-scale integrated data warehouse,information of 823 patients with UTO treated with Yinhua Miyanling tablets from February,2006 to December,2015 was extracted from 16 large grade-A comprehensive hospitals in China.Association rule analysis based on Apriori algorithm was used to analyze clinical prescription information.Results:After analyzing HIS database,the proportion of female patients with urinary system obstruction was higher than that of male patients(61.10%vs 38.90%),especially in the age group of 45~65.All patients were often complicated with urinary calculi and other diseases.The single dose of Yinhua Miyanling tablets was mainly 2 g(4 tablets),and the daily dose of 2.5~4 g(5~8 tablets)took up 87.99%;74.50%of the patients were treated for less than 7 days;97%were cured and improved after discharge.Conclusion:Urinary system obstruction caused by inflammatory reaction is the target treatment group of Yinhua Miyanling tablets.The treatment of 91.7%patients with urinary system obstruction with Yinhua Miyanling tablet needs to be combined with antibiotics.The combination regimen with antibiotics can be further chosen with Yinhua Miyanling combined with penicillin and amtraunan,Yinhua Miyanling tablets combined with penicillin and cefdinir,or Yinhua Miyanling tablets combined with piperacillin sodium and sulbactam sodium,according to drug sensitivity test results.Nearly half of the patients with urinary system obstruction needed to be treated with Chinese medicine clearing the heat;20.90%needed to be treated with combined tonifying Chinese medicine,and 11.06%with combined freeing strangury and removing stone drugs.

关 键 词：银花泌炎灵片 泌尿系梗阻 泌尿系感染 真实世界 精准人群 用药特征 联合用药 抗生素联用 

分 类 号：R289.5[医药卫生—方剂学]